Literature DB >> 10448278

Carbonyl reductase and NADPH cytochrome P450 reductase activities in human tumoral versus normal tissues.

A López de Cerain1, A Marín, M A Idoate, M T Tuñón, J Bello.   

Abstract

The use of bioreductive agents in enzyme-directed bioreductive therapy has been proposed to take advantage not only of hypoxia in tumours, but also of the presence of reductases that metabolise such compounds. In this study, we studied the activities of NADPH cytochrome P450 reductase (P450R) and carbonyl reductase (CR) in 17 human lung tumours and 18 human breast tumours, together with the corresponding normal tissues. For lung cancer but not for breast cancer there was a significant difference in the CR activity between normal and tumour tissue. CR activity was increased with respect to the normal tissue between 2-fold and 40-fold indicating heterogeneity in tumour samples. No relationship was found between CR activity and the histological type, tumoral grade or TNM stage of the tumours. Although some variation in P450R activity in tumoral versus normal tissues was found in the majority of the samples studied, no significant differences could be demonstrated.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10448278     DOI: 10.1016/s0959-8049(98)00372-4

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  5 in total

1.  Mechanistic basis for inflammation and tumor promotion in lungs of 2,6-di-tert-butyl-4-methylphenol-treated mice: electrophilic metabolites alkylate and inactivate antioxidant enzymes.

Authors:  Brent W Meier; Jose D Gomez; Oleg V Kirichenko; John A Thompson
Journal:  Chem Res Toxicol       Date:  2007-02       Impact factor: 3.739

2.  Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial.

Authors:  Ji-Yeob Choi; William E Barlow; Kathy S Albain; Chi-Chen Hong; Javier G Blanco; Robert B Livingston; Warren Davis; James M Rae; I-Tien Yeh; Laura F Hutchins; Peter M Ravdin; Silvana Martino; Alan P Lyss; C Kent Osborne; Martin D Abeloff; Daniel F Hayes; Christine B Ambrosone
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

Review 3.  Hypoxia and oxidative stress. Tumour hypoxia--therapeutic considerations.

Authors:  K J Williams; R L Cowen; I J Stratford
Journal:  Breast Cancer Res       Date:  2001-08-07       Impact factor: 6.466

4.  The role of cytochromes p450 and aldo-keto reductases in prognosis of breast carcinoma patients.

Authors:  Viktor Hlaváč; Veronika Brynychová; Radka Václavíková; Marie Ehrlichová; David Vrána; Václav Pecha; Markéta Trnková; Roman Kodet; Marcela Mrhalová; Kateřina Kubáčková; Jiří Gatěk; Petr Vážan; Pavel Souček
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

5.  Cytochrome P450 CYP1B1 activity in renal cell carcinoma.

Authors:  M C E McFadyen; W T Melvin; G I Murray
Journal:  Br J Cancer       Date:  2004-08-31       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.